




PHARMACEUTICAL 2019

Epizyme Inc.
Rank 95 of 363





PHARMACEUTICAL 2019

Epizyme Inc.
Rank 95 of 363



The relative strengths and weaknesses of Epizyme Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epizyme Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Epizyme Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 145% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	272,535
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	37,833
Liabilities, Non-Current	0
Other Assets	909
Other Compr. Net Income	-5.0
Other Expenses	57
Other Liabilities	0
Other Net Income	4,532
Other Revenues	21,700
Property and Equipment	2,057
Research and Development	105,833
Selling, General and Administrative Expense	43,972

Output Variable	Value in 1000 USD
Assets	275,501
Liabilities	37,833
Expenses	149,862
Revenues	21,700
Stockholders Equity	237,668
Net Income	-123,630
Comprehensive Net Income	-123,632
Economic Capital Ratio	182%